{"classes":[{"categories":[{"measurements":[{"comment":"Not enough events to calculate Median or Upper Limit.","groupId":"OG000","lowerLimit":"1.3","upperLimit":"NA","value":"NA"},{"comment":"Not enough events to calculate Median or Upper Limit.","groupId":"OG001","lowerLimit":"1.1","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"},{"groupId":"OG001","value":"6"}],"units":"Participants"}],"description":"PFS is defined as the time from start of study treatment to first documentation of objective tumor progression according to the Modified Lugano Criteria for Response Assessment (Cheson 2007) or to death due to any cause, whichever comes first.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with classic Hodgkin lymphoma","id":"OG000","title":"Classic Hodgkin Lymphoma"},{"description":"Participants with peripheral T cell lymphoma","id":"OG001","title":"PTCL"}],"paramType":"MEDIAN","populationDescription":"The full analysis set includes participants who received at least one dose of study treatment.","reportingStatus":"POSTED","timeFrame":"up to 18.3 months","title":"Progression-free Survival (PFS) Per BICR According to Modified Lugano Response Criteria","type":"SECONDARY","unitOfMeasure":"Months"}